Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/06—Peri-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
  • C07D513/20—Spiro-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

• Embodiments herein relate to compounds and methods for the treatment of RAS-mediated disease.
• embodiments herein relate to compounds and methods for treating diseases such as cancer via targeting oncogenic mutants of the K-RAS isoform.
• Ras proteins are small guanine nucleotide-binding proteins that act as molecular switches by cycling between active GTP-bound and inactive GDP-bound conformations. Ras signaling is regulated through a balance between activation by guanine nucleotide exchange factors (GEFs), most commonly son of sevenless (SOS), and inactivation by GTPase-activating proteins (GAPs) such as neurofibromin or p120GAP.
• GEFs guanine nucleotide exchange factors
• SOS son of sevenless
• GAPs GTPase-activating proteins
• the Ras proteins play an important role in the regulation of cell proliferation, differentiation, and survival. Dysregulation of the Ras signaling pathway is almost invariably associated with disease. Hyper-activating somatic mutations in Ras are among the most common lesions found in human cancer.
• K-Ras mutations are by far the most common in human cancer.
• K-Ras mutations are known to be often associated with pancreatic, colorectal and non-small-cell lung carcinomas.
• H-Ras mutations are common in cancers such as papillary thyroid cancer, lung cancers and skin cancers.
• N-Ras mutations occur frequently in hepatocellular carcinoma.
• embodiments disclosed herein relate to compounds of Formula (I)
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• Z 1 and Z 2 are independently CR 6 or N, with the proviso that at least one of Z 1 or Z 2 is CR 6 with R 6 being a bond to L 1 ;
• L 1 is linking group comprising at least one nitrogen atom;
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, alkoxy, aryl, heteroaryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, and arylthio with the proviso that:
• R 1 is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, or heteroaryl, any of which is optionally substituted;
• n is an integer from 1 to 3;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• R 6 is selected from the group consisting of hydrogen, alkyl, haloakyl, cyano, halo, alkoxy, aryl, heteroaryl, trifluoromethyl and bond to L 1 .
• embodiments herein relate to compounds according to any one of the compound tables provided herein.
• the compound tables are Table 2a, Table 3, Table 4, Table 5, Table 7, Table 8, Table 11, 12, and Table 13.
• embodiments herein relate to methods of treating cancer.
• the cancer comprises a K-RAs G12 mutation.
• the cancer is one or more of pancreatic, lung and colorectal cancer.
• the pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC).
• the cancer is a CNS cancer.
• the CNS cancer comprises a primary cancer.
• the primary cancer comprises one or more of a glioma, meningioma, medulloblastoma, ganblioglioma, schwannoma, and craniopharyngioma.
• the glioma comprises one or more of an astrocytoma, a glioblastoma, an oligodendroglioma, and a ependymoma.
• the CNS cancer comprises a metastatic or secondary cancer.
• the CNS cancer comprises a cancer metastasized from one or more of melanoma, breast cancer, colon cancer, kidney cancer, nasopharyngeal cancer, leukemia, lymphoma, myeloma, and other of unknown primary site.
• the CNS cancer comprises a RAS associated cancer.
• the compounds used in the methods provided herein may include any of the compounds found in Table 2a, Table 3, Table 4, Table 5, Table 7, Table 8, Table 11, 12, and Table 13
• potent and selective tricyclic quinazoline-2-ones compounds which have been found to be useful as inhibitors of oncogenic mutants of RAS proteins.
• the compounds disclosed herein are selective for oncogenic RAS mutants over wild-type RAS proteins.
• compounds disclosed herein may exhibit selectivity for oncogenic mutants of K-RAS over other mutated K-RAS proteins, as well as mutants of the N-RAS and H-RAS isoforms.
• the compounds disclosed herein may exhibit selectivity for K-RAS, N-RAS, and H-RAS mutants having a common G12C mutation.
• pharmaceutical compositions comprising these compounds, and their application in the treatment of disease, such as cancer.
• Methods of inhibition of oncogenic mutant K-RAS, N-RAS, and H-RAS activity are also provided, as well as methods for the treatment of oncogenic mutant RAS-mediated diseases, especially those involving elevated levels of oncogenic mutated RAS, in particular cancer. Accordingly, disclosed herein are uses of and methods of using the compounds described herein to treat one or more of the cancers described herein.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• Z 1 and Z 2 are independently CR 6 or N, with the proviso that at least one of Z 1 or Z 2 is CR 6 with R 6 being a bond to L 1 ;
• Z 3 is O;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, alkoxy, aryl, heteroaryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, and arylthio with the proviso that:
• R 1 is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, or heteroaryl, any of which is optionally substituted;
• n is an integer from 1 to 3;
• R 2 is selected from the group consisting of alkyl, alkylamino, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• R 6 is selected from the group consisting of hydrogen, alkyl, haloakyl, cyano, halo, alkoxy, aryl, heteroaryl, trifluoromethyl and bond to L 1 .
• inventions disclosed herein possess useful oncogenic mutant RAS inhibiting or modulating activity, and may be used in the treatment or prophylaxis of a disease or condition in which oncogenic mutant RAS plays an active role.
• embodiments disclosed herein also provide pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions.
• Embodiments disclosed herein provide methods for selectively inhibiting the RAS that are oncogenic mutants having the G12C mutation.
• methods for treating an oncogenic mutant K-RAS-mediated disorder in a subject comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition according to the various embodiments disclosed herein.
• Related embodiments disclose the use of the compounds disclosed herein as therapeutic agents, for example, in treating cancer and other diseases involving elevated levels of oncogenic mutant K-RAS.
• the various embodiments disclosed herein also contemplate the use of the compounds disclosed herein for use in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the inhibition of oncogenic mutant K-RAS.
• the disease or condition is cancer.
• Each of the aforementioned methods apply equally to the similar mutation in N-RAS and H-RAS bearing the G12C mutation.
• compounds of the various embodiments disclosed herein may be selective amongst the RAS oncogenic mutant forms in various ways.
• compounds described herein may be selective for G12C mutants of K-RAS, N-RAS, or H-RAS.
• compounds of the various embodiments disclosed herein may be selective for K-RAS G12C over other K-RAS mutants and Wild Type K-RAS.
• compounds of various embodiments disclosed herein may be selective for N-RAS and H-RAS bearing the same G12C mutation.
• CNS cancer can include any cancer of the CNS including cancer of the brain, spinal cord and nerves.
• CNS cancers can include, for example, primary cancers (e.g., those that start in the brain) and secondary or metastatic CNS cancers (those that do not start in the CNS but metastasize to the CNS).
• Any CNS cancer is contemplated including without limitation, for example, gliomas (including astrocytomas and glioblastomas, oligodendrogliomas, ependymomas), meningiomas, medulloblastomas, ganbliogliomas, schwannomas, and craniopharyngiomas.
• Any metastatic CNS cancer is contemplated, including without limitation, a cancer metastasized to the CNS via metastases of melanoma, breast cancer, colon cancer, kidney cancer, nasopharyngeal cancer, lymphoma, myeloma, leukemia, and other cancers of unknown primary site.
• the various embodiments disclosed herein also relate to methods of inhibiting at least one RAS function comprising the step of contacting an oncogenic mutant RAS with a compound of Formula I or any of the compounds from the tables, as described herein.
• the cell phenotype, cell proliferation, activity of the mutant RAS, change in biochemical output produced by active mutant RAS, expression of mutant RAS, or binding of mutant RAS with a natural binding partner may be affected.
• Such methods may be embrace modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.
• A,” “an,” or “the” as used herein not only include aspects with one member, but also include aspects with more than one member.
• the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
• reference to “a cell” includes a plurality of such cells and reference to “the agent” includes reference to one or more agents known to those skilled in the art, and so forth.
• acyl refers to a carbonyl (C ⁇ O) attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, or any other moiety were the atom attached to the carbonyl is carbon.
• An “acetyl” group which is a type of acyl, refers to a (—C( ⁇ O)CH 3 ) group.
• An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include, without limitation, methylcarbonyl and ethylcarbonyl.
• an “arylcarbonyl” or “aroyl” group refers to an aryl group attached to the parent molecular moiety through a carbonyl group.
• examples of such groups include, without limitation, benzoyl and naphthoyl.
• generic examples of acyl groups include alkanoyl, aroyl, heteroaroyl, and so on.
• Specific examples of acyl groups include, without limitation, formyl, acetyl, acryloyl, benzoyl, trifluoroacetyl and the like.
• alkenyl refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, the alkenyl may comprise from 2 to 6 carbon atoms, or from 2 to 4 carbons, either of which may be referred to as “lower alkenyl.”
• alkenylene refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene (—CH ⁇ CH—).
• Alkenyl can include any number of carbons, such as C 2 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 2-7 , C 2-8 , C 2-9 , C 2-10 , C 3 , C 3-4 , C 3-5 , C 3-6 , C 4 , C 4-5 , C 4-6 , C 5 , C 5-6 , and C 6 , and so on up to 20 carbon atoms.
• Alkenyl groups can have any suitable number of double bonds, including, but not limited to, 1, 2, 3, 4, 5 or more.
• alkenyl groups include, but are not limited to, vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl.
• Alkenyl groups can be substituted or unsubstituted. Unless otherwise specified, the term “alkenyl” may include “alkenylene” groups.
• alkoxy refers to an alkyl ether radical, wherein the term alkyl is as defined below.
• Alkoxy groups may have the general formula: alkyl-O—.
• alkyl group alkoxy groups can have any suitable number of carbon atoms, such as C1_6.
• Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, and the like.
• the alkoxy groups can be further optionally substituted as defined herein.
• alkyl refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, the alkyl may comprise from 1 to 10 carbon atoms. In further embodiments, the alkyl may comprise from 1 to 6 carbon atoms, or from 1 to 4 carbon atoms.
• Alkyl can include any number of carbons, such as C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 1-7 , C 1-8 , C 1-9 , C 1-10 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 .
• C 1-6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc.
• Alkyl can also refer to alkyl groups having up to 20 carbons atoms, such as, but not limited to heptyl, octyl, nonyl, decyl, etc. Alkyl groups can be substituted or unsubstituted.
• alkylene refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH 2 —). Unless otherwise specified, the term “alkyl” may include “alkylene” groups. When the alkyl is methyl, it may be represented structurally as CH 3 , Me, or just a single bond terminating with no end group substitution.
• alkylamino refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino (—NHMe), N-ethylamino (—NHEt), N,N-dimethylamino (—NMe 2 ), N,N-ethylmethylamino (—NMeEt) and the like.
• aminoalkyl refers to reverse orientation in which the amino group appears distal to the parent molecular moiety and attachment to the parent molecular moiety is through the alkyl group.
• NH 2 (CH 2 ) n — describes an aminoalkyl group with a terminal amine at the end of an alkyl group attached to the parent molecular moiety.
• alkylamino and aminoalkyl can be combined to describe an “alkylaminoalkyl” group in which an alkyl group resides on a nitrogen atom distal to the parent molecular moiety, such as MeNH(CH 2 ) n —.
• an aryl group as defined herein, may combine in a similar fashion providing an arylaminoalkyl group ArNH(CH 2 ) n —.
• N- in the name, such as N-arylaminoalkyl, which is understood to mean that the aryl group is a substituent on the nitrogen atom of the aminoalkyl group, the alkyl being attached the parent molecular moiety.
• alkylidene refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.
• alkylthio refers to an alkyl thioether (AlkS—) radical wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized.
• suitable alkyl thioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.
• arylthio refers to arylthioether (ArS—) radical wherein the term aryl is as defined herein and wherein the sulfur may be singly or double oxidized.
• alkynyl refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms.
• alkynylene refers to a carbon-carbon triple bond attached at two positions such as ethynylene.
• Alkynyl can include any number of carbons, such as C 2 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 2-7 , C 2-8 , C 2-9 , C 2-10 , C 3 , C 3-4 , C 3-5 , C 3-6 , C 4 , C 4-5 , C 4-6 , C 5 , C 5-6 , and C 6 .
• alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatriynyl.
• Alkynyl groups can be substituted or unsubstituted. Unless otherwise specified, the term “alkynyl” may include “alkynylene” groups.
• acylamino as used herein, alone or in combination, refers to an amino group as described below attached to the parent molecular moiety through a carbonyl group.
• C-amido as used herein, alone or in combination, refers to a —C( ⁇ O)N(R) 2 group where is R as defined herein.
• N-amido as used herein, alone or in combination, refers to RC( ⁇ O)N(R′)— group, with R and R′ as defined herein.
• acylamino as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group.
• An example of an “acylamino” group is acetylamino (CH 3 C(O)NH—).
• amino refers to —N(R)(R′) or —N + (R)(R′)(R′′), wherein R, R′ and R′′ are independently selected from the group consisting of hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted.
• amino acid means a substituent of the form —NRCH(R′)C(O)OH, wherein R is typically hydrogen, but may be cyclized with N (for example, as in the case of the amino acid proline), and R′ is selected from the group consisting of hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, amido, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, thiol, thioalkyl, alkylthioalkyl, and alkylthio, any of which may be optionally substituted.
• amino acid includes all naturally occurring amino acids as well as synthetic analogues.
• aryl as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused.
• aryl embraces aromatic radicals such as benzyl, phenyl, naphthyl, anthracenyl, phenanthryl, indanyl, indenyl, annulenyl, azulenyl, tetrahydronaphthyl, and biphenyl.
• arylalkenyl or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
• arylalkoxy or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
• arylalkyl or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.
• arylalkynyl or “aralkynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
• arylalkanoyl or “aralkanoyl” or “aroyl,” as used herein, alone or in combination, refers to an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.
• aryloxy refers to an aryl group attached to the parent molecular moiety through an oxy.
• benzo and “benz,” as used herein, alone or in combination, refer to the divalent radical C 6 H 4 — derived from benzene. Examples include benzothiophene and benzimidazole.
• carbamate refers to an ester of carbamic acid (—NHCOO—) which may be attached to the parent molecular moiety from either the nitrogen or acid (oxygen) end, and which may be optionally substituted as defined herein.
• O-carbamyl as used herein, alone or in combination, refers to a —OC(O)NRR′, group, with R and R′ as defined herein.
• N-carbamyl as used herein, alone or in combination, refers to a ROC(O)NR′— group, with R and R′ as defined herein.
• carbonyl when alone includes formyl [—C( ⁇ O)H] and in combination is a —C( ⁇ O)— group.
• carboxyl refers to —C( ⁇ O)OH, O-carboxy, C-carboxy, or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt.
• An “O-carboxy” group refers to a RC( ⁇ O)O— group, where R is as defined herein.
• a “C-carboxy” group refers to a —C( ⁇ O)OR groups where R is as defined herein.
• cyano as used herein, alone or in combination, refers to —CN.
• cycloalkyl refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl radical wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein.
• a cycloalkyl may comprise from from 3 to 7 carbon atoms, or from 5 to 7 carbon atoms.
• cycloalkyl radicals examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl and the like.
• “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[1.1.1]pentane, camphor, adamantane, and bicyclo[3.2.1]octane.
• electrophilic moiety is used in accordance with its plain ordinary chemical meaning and refers to a chemical group that is electrophilic.
• Exemplary electrophilic moieties include, without limitation, unsaturated carbonyl containing compounds such as acrylamides, acrylates, unsaturated (i.e., vinyl) sulfones or phosphates, epoxides, and vinyl epoxides.
• esters refers to a carboxyl group bridging two moieties linked at carbon atoms (—CRR′C( ⁇ O)OCRR′—), where each R and R′ are independent and defined herein.
• ether typically refers to an oxy group bridging two moieties linked at carbon atoms. “Ether” may also include polyethers, such as, for example, —RO(CH 2 ) 2 O(CH 2 ) 2 O(CH 2 ) 2 OR′, —RO(CH 2 ) 2 O(CH 2 ) 2 OR′, —RO(CH 2 ) 2 OR′, and —RO(CH 2 ) 2 OH.
• halo or halogen, as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.
• haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
• haloalkyl refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl, trihaloalkyl and polyhaloalkyl radicals.
• a monohaloalkyl radical for one example, may have an iodo, bromo, chloro or fluoro atom within the radical.
• Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.
• haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
• Haloalkylene refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (—CFH—), difluoromethylene (—CF 2 —), chloromethylene (—CHCl—) and the like.
• heteroalkyl refers to a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized (i.e. bond to 4 groups).
• the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, —CH 2 NHOCH 3 .
• the term heteroalkyl may include ethers.
• heteroaryl refers to 3 to 7 membered unsaturated heteromonocyclic rings, or fused polycyclic rings, each of which is 3 to 7 membered, in which at least one of the fused rings is unsaturated, wherein at least one atom is selected from the group consisting of O, S, and N.
• a heteroaryl may comprise from 5 to 7 carbon atoms.
• the term also embraces fused polycyclic groups wherein heterocyclic radicals are fused with aryl radicals, wherein heteroaryl radicals are fused with other heteroaryl radicals, or wherein heteroaryl radicals are fused with cycloalkyl radicals.
• heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chro
• Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.
• Heteroaryl groups can include any number of ring atoms, such as, 5 to 6, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 3 to 9, 3 to 10, 3 to 11, or 3 to 12 ring members. Any suitable number of heteroatoms can be included in the heteroaryl groups, such as 1, 2, 3, 4, or 5, or 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, 2 to 5, 3 to 4, or 3 to 5. Heteroaryl groups can have from 5 to 8 ring members and from 1 to 4 heteroatoms, or from 5 to 8 ring members and from 1 to 3 heteroatoms, or from 5 to 6 ring members and from 1 to 4 heteroatoms, or from 5 to 6 ring members and from 1 to 3 heteroatoms.
• the heteroaryl group can include groups such as pyrrole, pyridine, imidazole, pyrazole, triazole, tetrazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
• heteroaryl groups can also be fused to aromatic ring systems, such as a phenyl ring, to form members including, but not limited to, benzopyrroles such as indole and isoindole, benzopyridines such as quinoline and isoquinoline, benzopyrazine (quinoxaline), benzopyrimidine (quinazoline), benzopyridazines such as phthalazine and cinnoline, benzothiophene, and benzofuran.
• Other heteroaryl groups include heteroaryl rings linked by a bond, such as bipyridine. Heteroaryl groups can be substituted or unsubstituted.
• the heteroaryl groups can be linked via any position on the ring.
• pyrrole includes 1-, 2- and 3-pyrrole
• pyridine includes 2-, 3- and 4-pyridine
• imidazole includes 1-, 2-, 4- and 5-imidazole
• pyrazole includes 1-, 3-, 4- and 5-pyrazole
• triazole includes 1-, 4- and 5-triazole
• tetrazole includes 1- and 5-tetrazole
• pyrimidine includes 2-, 4-, 5- and 6-pyrimidine
• pyridazine includes 3- and 4-pyridazine
• 1,2,3-triazine includes 4- and 5-triazine
• 1,2,4-triazine includes 3-, 5- and 6-triazine
• 1,3,5-triazine includes 2-triazine
• thiophene includes 2- and 3-thiophene
• furan includes 2- and 3-furan
• thiazole includes 2-, 4- and 5-thiazole
• isothiazole includes 3-, 4- and 5-is
• heteroaryl groups include those having from 5 to 10 ring members and from 1 to 3 ring atoms including N, O or S, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, isoxazole, indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, and benzofuran.
• N, O or S such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,
• heteroaryl groups include those having from 5 to 8 ring members and from 1 to 3 heteroatoms, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
• heteroatoms such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
• heteroaryl groups include those having from 9 to 12 ring members and from 1 to 3 heteroatoms, such as indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, benzofuran and bipyridine.
• heteroaryl groups include those having from 5 to 6 ring members and from 1 to 2 ring atoms including N, O or S, such as pyrrole, pyridine, imidazole, pyrazole, pyrazine, pyrimidine, pyridazine, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
• heterocycloalkyl and, interchangeably, “heterocycle,” or “heterocyclyl” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated monocyclic, bicyclic, or tricyclic heterocyclic radical containing at least one heteroatom as ring members, wherein each heteroatom may be independently selected from the group consisting of nitrogen, oxygen, and sulfur.
• a heterocycloalkyl may comprise from 1 to 4 heteroatoms as ring members.
• a heterocycloalkyl may comprise from 1 to 2 heteroatoms ring members.
• a heterocycloalkyl may comprise from 3 to 8 ring members in each ring.
• a heterocycloalkyl may comprise from 3 to 7 ring members in each ring. In yet further embodiments, a heterocycloalkyl may comprise from 5 to 6 ring members in each ring.
• “Heterocycloalkyl” and “heterocycle” are intended to include sugars, sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group.
• heterocycloalkyl groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihy-dropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, epoxy, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like.
• the heterocycloalkyl groups may be optionally substituted unless specifically prohibited.
• Heterocycloalkyl may refer to a saturated ring system having from 3 to 12 ring members and from 1 to 5 heteroatoms of N, O and S.
• the heteroatoms can also be oxidized, such as, but not limited to, S(O) and S(O) 2 .
• Heterocycloalkyl groups can include any number of ring atoms, such as, 3 to 6, 4 to 6, 5 to 6, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 3 to 9, 3 to 10, 3 to 11, or 3 to 12 ring members. Any suitable number of heteroatoms can be included in the heterocycloalkyl groups, such as 1, 2, 3, 4, or 5, or 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, 2 to 5, 3 to 4 or 3 to 5.
• the heterocycloalkyl group can include any number of carbons, such as C 3-6 , C 4-6 , C 5-6 , C 3-8 , C 4-8 , C 5-8 , C 6-8 , C 3-9 , C 3-10 , C 3-11 , and C 3-12 .
• the heterocycloalkyl group can include groups such as aziridine, azetidine, pyrrolidine, piperidine, azepane, diazepane, azocane, quinuclidine, pyrazolidine, imidazolidine, piperazine (1,2-, 1,3- and 1,4-isomers), oxirane, oxetane, tetrahydrofuran, oxane (tetrahydropyran), oxepane, thiirane, thietane, thiolane (tetrahydrothiophene), thiane (tetrahydrothiopyran), oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, dioxolane, dithiolane, morpholine, thiomorpholine, dioxane, or dithiane.
• groups such as aziridine, azetidine, pyrrolidine,
• heterocycloalkyl groups can also be fused to aromatic or non-aromatic ring systems to form members including, but not limited to, indoline, diazabicycloheptane, diazabicyclooctane, diazaspirooctane or diazaspirononane.
• Heterocycloalkyl groups can be unsubstituted or substituted.
• heterocycloalkyl groups can be substituted with C1 6 alkyl or oxo ( ⁇ O), among many others.
• Heterocycloalkyl groups can also include a double bond or a triple bond, such as, but not limited to dihydropyridine or 1,2,3,6-tetrahydropyridine.
• the heterocycloalkyl groups can be linked via any position on the ring.
• aziridine can be 1- or 2-aziridine
• azetidine can be 1- or 2-azetidine
• pyrrolidine can be 1-, 2- or 3-pyrrolidine
• piperidine can be 1-, 2-, 3- or 4-piperidine
• pyrazolidine can be 1-, 2-, 3-, or 4-pyrazolidine
• imidazolidine can be 1-, 2-, 3- or 4-imidazolidine
• piperazine can be 1-, 2-, 3- or 4-piperazine
• tetrahydrofuran can be 1- or 2-tetrahydrofuran
• oxazolidine can be 2-, 3-, 4- or 5-oxazolidine
• isoxazolidine can be 2-, 3-, 4- or 5-isoxazolidine
• thiazolidine can be 2-, 3-, 4- or 5-thiazolidine
• isothiazolidine can be 2-, 3-, 4- or 5-isothiazolidine
• heterocycloalkyl includes 3 to 8 ring members and 1 to 3 heteroatoms
• representative members include, but are not limited to, pyrrolidine, piperidine, tetrahydrofuran, oxane, tetrahydrothiophene, thiane, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxzoalidine, thiazolidine, isothiazolidine, morpholine, thiomorpholine, dioxane and dithiane.
• Heterocycloalkyl can also form a ring having 5 to 6 ring members and 1 to 2 heteroatoms, with representative members including, but not limited to, pyrrolidine, piperidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, and morpholine.
• hydrazinyl refers to two amino groups joined by a single bond, i.e., —N—N—.
• the hydrazinyl group has optional substitution on at least one NH hydrogen to confer stability.
• hydroxamic acid or its ester as used herein, refers to —C(O)ON(R)O(R′), wherein R and R′ are as defined herein, or the corresponding “hydroxamate” anion, including any corresponding hydroxamic acid salt.
• hydroxyalkyl refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.
• “Hydroxyalkyl” or “alkylhydroxy” refers to an alkyl group, as defined above, where at least one of the hydrogen atoms is replaced with a hydroxy group.
• hydroxyalkyl or alkylhydroxy groups can have any suitable number of carbon atoms, such as C 1-6 .
• Exemplary C 1-4 hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl (where the hydroxy is in the 1- or 2-position), hydroxypropyl (where the hydroxy is in the 1-, 2- or 3-position), hydroxybutyl (where the hydroxy is in the 1-, 2-, 3- or 4-position), 1,2-dihydroxyethyl, and the like.
• amino as used herein, alone or in combination, refers to C ⁇ NR.
• aminohydroxy refers to C ⁇ N(OH) and it O-ether C ⁇ N—OR.
• isocyanato refers to a —NCO group.
• isothiocyanato refers to a —NCS group.
• linear chain of atoms refers to the longest straight chain of atoms independently selected from carbon, nitrogen, oxygen and sulfur.
• linking group refers to any nitrogen containing organic fragment that serves to connect the pyrimidine or pyridone core of the compounds disclosed herein to the electrophilic moiety E, as defined herein.
• exemplary linking groups include piperazines, aminoalkyls, alkyl- or aryl-based diamines, aminocycloalkyls, amine-containing spirocyclics, any of which may be optionally substituted as defined herein.
• linking groups may comprise the substructure L-Q-L′-E wherein Q is a monocyclic 4 to 7 membered ring or a bicyclic, bridged, or fused, or spiro 6-11 membered ring, any of which optionally include one or more nitrogen atoms, E is the electrophilic group, L is bond, C 1-6 alkylene, —O—C 0-5 alkylene, —S—C 0-5 alkylene, or —NH—C 0-5 alkylene, and for C 2-6 alkylene, —O—C 2-5 alkylene, —S—C 2-5 alkylene, and N—HC 2-5 alkylene, one carbon atom of any of the alkylene groups can optionally be replaced with O, S, or NH; and L′ is bond when Q comprises a nitrogen to link to E, otherwise L′ is NR, where R is hydrogen or alkyl.
• lower means containing from 1 to and including 6 carbon atoms, or from 1 to 4 carbon atoms.
• mercaptyl as used herein, alone or in combination, refers to an RS-group, where R is as defined herein.
• nitro refers to —NO 2 .
• oxy or “oxa,” as used herein, alone or in combination, refer to —O—.
• perhaloalkoxy refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
• perhaloalkyl refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
• phosphoamide refers to a phosphate group [(OH) 2 P( ⁇ O)O—] in which one or more of the hydroxyl groups has been replaced by nitrogen, amino, or amido.
• phosphonate refers to a group of the form ROP(OR′)(OR)O— wherein R and R′ are selected from the group consisting of hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted.
• Phosphonate includes “phosphate [(OH) 2 P(O)O—] and related phosphoric acid anions which may form salts.
• sulfonate refers to the —SO 3 H group and its anion as the sulfonic acid is used in salt formation or sulfonate ester where OH is replaced by OR, where R is not hydrogen, but otherwise is as defined herein, and typically being alkyl or aryl.
• sulfonyl as used herein, alone or in combination, refers to —S(O) 2 —.
• N-sulfonamido refers to a RS( ⁇ O) 2 NR′— group with R and R′ as defined herein.
• S-sulfonamido refers to a —S( ⁇ O) 2 NRR′, group, with R and R′ as defined herein.
• thia and thio refer to a —S— group or an ether wherein the oxygen is replaced with sulfur.
• the oxidized derivatives of the thio group namely sulfinyl and sulfonyl, are included in the definition of thia and thio.
• thiol as used herein, alone or in combination, refers to an —SH group.
• thiocarbonyl when alone includes thioformyl —C( ⁇ S)H and in combination is a —C( ⁇ S)— group.
• N-thiocarbamyl refers to an ROC( ⁇ S)NR′— group, with R and R′ as defined herein.
• O-thiocarbamyl refers to a —OC( ⁇ S)NRR′, group with R and R′ as defined herein.
• thiocyanato refers to a —CNS group.
• trihalomethanesulfonamido refers to a X 3 CS( ⁇ O) 2 NR— group with X is a halogen and R as defined herein.
• trihalomethanesulfonyl refers to a X 3 CS( ⁇ O) 2 — group where X is a halogen.
• trihalomethoxy refers to a X 3 CO— group where X is a halogen.
• trimethysilyl as used herein, alone or in combination, refers to a silicone group substituted at its three free valences with groups as listed herein under the definition of substituted amino. Examples include trimethysilyl, tert-butyldimethylsilyl, triphenylsilyl and the like.
• any one of the positions that is understood to have a hydrogen may also exist or understood to be isotopically enriched.
• any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Obtaining 100% deuteration at any relevant site of a compound in an amount of milligram or greater can be difficult. Therefore, it is understood that some percentage of hydrogen may still be present, even though a deuterium atom is specifically shown in a chemical structure.
• a chemical structure contains a “D”
• the compound represented by the structure is deuterium-enriched at the site represented by “D.”
• a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its natural abundance isotopic composition.
• a position is designated specifically as “D” or “deuterium,” the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., the term “D” or “deuterium” indicates at least 50.1% incorporation of deuterium).
• a benzene ring may be optionally exist as —C 6 D 5 , —C 6 DH 4 , —C 6 D 2 H 3 , —C 6 D 3 H 2 , and —C 6 D 4 H.
• a cyclohexyl group may optionally exist as —C 6 D 11 .
• any definition herein may be used in combination with any other definition to describe a composite structural group.
• the trailing element of any such definition is that which attaches to the parent moiety.
• the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group
• the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.
• null When a group is defined to be “null,” what is meant is that said group is absent.
• a “null” group occurring between two other group may also be understood to be a collapsing of flanking groups. For example, if in —(CH 2 ) x G 1 G 2 G 3 , the element G 2 were null, said group would become —(CH 2 ) x G 1 G 3 .
• optionally substituted means the anteceding group or groups may be substituted or unsubstituted. Groups constituting optional substitution may themselves be optionally substituted. For example, where an alkyl group is embraced by an optional substitution, that alkyl group itself may also be optionally substituted.
• the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: alkyl, alkenyl, alkynyl, alkanoyl, heteroalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, lower perhaloalkyl, perhaloalkoxy, cycloalkyl, phenyl, aryl, aryloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl, carboxyl, alkylcarbonyl, carboxyester, carboxamido, cyano, hydrogen, halogen, hydroxy, amino, alkylamino, arylamino, amido, nitro, thiol, alkylthio, haloalkylthio, perhaloalkylthio, arylthi
• optional substitution include, without limitation: (1) alkyl, halo, and alkoxy; (2) alkyl and halo; (3) alkyl and alkoxy; (4) alkyl, aryl, and heteroaryl; (5) halo and alkoxy; and (6) hydroxyl, alkyl, halo, alkoxy, and cyano.
• an optional substitution comprises a heteroatom-hydrogen bond (—NH—, SH, OH)
• further optional substitution of the heteroatom hydrogen is contemplated and includes, without limitation optional substitution with alkyl, acyl, alkoxymethyl, alkoxyethyl, arylsulfonyl, alkyl sulfonyl, any of which are further optionally substituted.
• Optionally substituted may include any of the chemical functional groups defined hereinabove and throughout this disclosure. Two optional substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy.
• An optionally substituted group may be unsubstituted (e.g., —CH 2 CH 3 ), fully substituted (e.g., —CF 2 CF 3 ), monosubstituted (e.g., —CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., —CH 2 CF 3 ).
• a carbon chain may be substituted with an alkyl group, a halo group, and an alkoxy group.
• substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed.
• substituent is qualified as “substituted,” the substituted form is specifically intended.
• different sets of optional substituents to a particular moiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted with.”
• R or the term R′ refers to a moiety selected from the group consisting of hydrogen, hydroxyl, halogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted.
• R and R′ groups should be understood to be optionally substituted as defined herein.
• Asymmetric centers, axial asymmetry (non-interchanging rotamers), or the like may exist in the compounds of the various embodiments disclosed herein. Such chirality may be designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom or the relevant axis. It should be understood that embodiments encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, d-isomers and 1-isomers, and mixtures thereof.
• Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art.
• Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.
• the compounds of the various embodiments disclosed herein may exist as geometric isomers.
• the various embodiments disclosed herein includes all cis, trans, syn, anti,
• E
• Z tautomers
• compounds may exist as tautomers, including keto-enol tautomers; all tautomeric isomers are embraced by the embodiments disclosed herein.
• the compounds of the various embodiments disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
• the solvated forms are considered equivalent to the unsolvated forms for the purposes of the various embodiments disclosed herein.
• bonds refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered part of larger substructure.
• a bond may be single, double, or triple unless otherwise specified.
• a dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.
• the compounds disclosed herein can exist as pharmaceutically acceptable salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002). It is understood that each of the compounds disclosed herein, and each embodiment of the compounds set forth herein, include pharmaceutically acceptable salts of such compounds.
• the salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid.
• Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenyl
• basic groups in the compounds of the various embodiments disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
• acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion.
• the various embodiments disclosed herein contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
• Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxyl group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
• a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
• the cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine.
• Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
• disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder” and “condition” (as in medical condition), in that all reflect an abnormal condition of the body or of one of its parts that impairs normal functioning and is typically manifested by distinguishing signs and symptoms.
• the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g., but not limited to, humans), including leukemia, lymphomas, carcinomas and sarcomas.
• the cancer is a metastatic cancer.
• a metastatic cancer is a cancer that has metastasized, e.g., the subject has developed a secondary malignant growth(s) at a distance from a primary (original) site of the cancer.
• the new, metastatic tumor is the same type of cancer as the primary tumor.
• metastasis occurs via the central nervous system and the compounds disclosed herein can ameliorate spread of the cancer via the CNS.
• Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, the central nervous system (“CNS,” e.g., brain, spine and nerves), breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, Medulloblastoma, colorectal cancer, pancreatic cancer (specifically including pancreatic ductal adenocarcinoma (PDAC)).
• CNS central nervous system
• PDAC pancreatic ductal adenocarcinoma
• Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
• leukemia refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic).
• Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia,lymphogenous leukemia
• lymphoma refers to a group of cancers affecting hematopoietic and lymphoid tissues. It begins in lymphocytes, the blood cells that are found primarily in lymph nodes, spleen, thymus, and bone marrow. Two main types of lymphoma are non-Hodgkin lymphoma and Hodgkin's disease. Hodgkin's disease represents approximately 15% of all diagnosed lymphomas. This is a cancer associated with Reed-Sternberg malignant B lymphocytes. Non-Hodgkin's lymphomas (NHL) can be classified based on the rate at which cancer grows and the type of cells involved. There are aggressive (high grade) and indolent (low grade) types of NHL.
• B-cell and T-cell NHLs Based on the type of cells involved, there are B-cell and T-cell NHLs.
• Exemplary B-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, small lymphocytic lymphoma, Mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodal (monocytoid B-cell) lymphoma, splenic lymphoma, diffuse large cell B-lymphoma, Burkitt's lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B-lymphoblastic lymphoma.
• T-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, cunateous T-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, and precursor T-lymphoblastic lymphoma.
• sarcoma generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
• Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma,
• melanoma is taken to mean a tumor arising from the melanocytic system of the skin and other organs.
• Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
• carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
• exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epier
• CNS cancer can include any cancer of the CNS including cancer of the brain, spinal cord and nerves.
• CNS cancers can include, for example, primary cancers (e.g., those that start in the brain) and secondary or metastatic cancers CNS cancers (those that do not start in the CNS but metastasize to the CNS).
• Any CNS cancer is contemplated including without limitation, those listed elsewhere herein and gliomas (including astrocytomas and glioblastomas, oligodendrogliomas, ependymomas), meningiomas, medulloblastomas, ganbliogliomas, schwannomas, and craniopharyngiomas.
• Any metastatic CNS cancer is contemplated, including without limitation, a cancer metastasized to the CNS from metastases of melanoma, breast cancer, colon cancer, kidney cancer, nasopharyngeal cancer, and other of unknown primary site.
• Compounds described herein have the ability penetrate the CNS in order to treat CNS cancers, both primary and metastatic.
• the treatments can include treating a cancer originated in the CNS that metastasizes to other parts of the CNS or outside of the CNS.
• compounds disclosed herein can also prevent or reduce metastatic pathways via the CNS.
• Ras associated cancer refers to a cancer caused by aberrant Ras activity or signaling.
• a “cancer associated with aberrant K-Ras activity” is a cancer caused by aberrant K-Ras activity or signaling (e.g. a mutant K-Ras).
• K-Ras related cancers may include lung cancer, non-small cell lung cancer, breast cancer, leukemia, pancreatic cancer, colon cancer, colorectal cancer.
• cancers that are associated with aberrant activity of one or more of Ras, K-Ras, H-Ras, N-Ras, mutant K-Ras (including K-Ras G12C, K-Ras G12V, K-Ras G13C, K-Ras G12D, K-Ras G13D mutants), mutant N-Ras, and mutant H-Ras are well known in the art, including G12C in both N-Ras and H-Ras, and determining such cancers are within the skill of a person of skill in the art.
• administering means administering a compound that inhibits the activity or level (e.g. amount) or level of a signaling pathway of one or more Ras proteins (e.g. a Ras inhibitor, K-Ras inhibitor, N-Ras inhibitor, H-Ras inhibitor, mutant K-Ras inhibitor, K-Ras G12C inhibitor, K-Ras G12V inhibitor, K-Ras G13C inhibitor, K-Ras G12D inhibitor, K-Ras G13D inhibitor) to a subject.
• Administration may include, without being limited by mechanism, allowing sufficient time for the Ras inhibitor to reduce the activity of one or more Ras proteins or for the Ras inhibitor to reduce one or more symptoms of a disease (e.g.
• administering means administering a compound that inhibits the activity or level (e.g. amount) or level of a signaling pathway of one or more K-Ras proteins (K-Ras, mutant K-Ras, K-Ras G12C, K-Ras G12V, K-Ras G12D, K-Ras G13C, K-Ras G13D).
• the administering does not include administration of any active agent other than the recited active agent.
• a disease e.g. Ras (e.g., human K-Ras or human H-Ras) activity, a protein associated disease, a cancer associated with aberrant Ras activity, K-Ras associated cancer, mutant K-Ras associated cancer, activated K-Ras associated cancer, K-RasG12C associated cancer, K-Ras G12V associated cancer, K-Ras G13C associated cancer, K-Ras G12D associated cancer, K-Ras G13D associated cancer) means that the disease (e.g.
• Ras e.g., human K-Ras or human H-Ras) activity, a protein associated disease, a cancer associated with aberrant Ras activity, K-Ras associated cancer, mutant K-Ras associated cancer, activated K-Ras associated cancer, K-RasG12C associated cancer, K-Ras G12V associated cancer, K-Ras G13C associated cancer, K-Ras G12D associated cancer, K-Ra
• a cancer associated with aberrant Ras activity or function may be a cancer that results (entirely or partially) from aberrant Ras activity or function (e.g. enzyme activity, protein-protein binding, signaling pathway) or a cancer wherein a particular symptom of the disease is caused (entirely or partially) by aberrant Ras activity or function.
• aberrant Ras activity or function e.g. enzyme activity, protein-protein binding, signaling pathway
• a cancer wherein a particular symptom of the disease is caused (entirely or partially) by aberrant Ras activity or function.
• what is described as being associated with a disease if a causative agent, could be a target for treatment of the disease.
• a cancer associated with aberrant Ras activity or function or a Ras associated cancer may be treated with a Ras modulator or Ras inhibitor, in the instance where increased Ras activity or function (e.g., signaling pathway activity) causes the cancer.
• a cancer associated with K-Ras G12C may be a cancer that a subject with K-Ras G12C is at higher risk of developing as compared to a subject without K-Ras G12C.
• a cancer associated with K-Ras G12V may be a cancer that a subject with K-Ras G12V is at higher risk of developing as compared to a subject without K-Ras G12V.
• Ras GTPase proteins e.g. K-Ras, H-Ras, N-Ras.
• K-Ras refers to the nucleotide sequences or proteins of human K-Ras (e.g. human K-Ras4A (NP 203524.1), human K-Ras4B (NP 004976.2), or both K-Ras4A and K-Ras4B).
• K-Ras includes both the wild-type form of the nucleotide sequences or proteins as well as any mutants thereof. In some embodiments, “K-Ras” is wild-type K-Ras.
• K-Ras is one or more mutant forms.
• K-Ras” XYZ refers to a nucleotide sequence or protein of a mutant K-Ras wherein the Y numbered amino acid of K-Ras that has an X amino acid in the wildtype instead has a Z amino acid in the mutant (e.g. K-Ras G12C has a Gin wildtype protein but a C in the K-Ras G12C mutantprotein).
• K-Ras refers to K-Ras4A and K-Ras4B.
• K-Ras refers to K-Ras4A.
• K-Ras refers to K-Ras4B (e.g., NM 004985.4 or NP 004976.2).
• K-Ras refers to the protein including (e.g., consisting of) the amino acid sequence below or including the sequence below with one or more mutations (e.g., G12C, G12V, or G13C):
• K-Ras refers to the protein including (e.g., consisting of) the amino acid sequence below or including (e.g., consisting of) the sequence below with one or more mutations (e.g., G12C, G12V, or G13C):
• combination therapy means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
• K-RAS inhibitor is used herein to refer to a compound that exhibits an IC 50 with respect to K-RAS activity of no more than about 100 mM and more typically not more than about 50 mM, as measured in the K-RAS assay described generally hereinbelow.
• IC 50 is that concentration of inhibitor that reduces the activity of an enzyme (e.g., K-RAS) to half-maximal level.
• K-RAS an enzyme
• compounds will exhibit an IC 50 with respect to oncogenic mutant K-RAS of no more than about 10 mM; in further embodiments, compounds will exhibit an IC 50 with respect to K-RAS of no more than about 5 mM; in yet further embodiments, compounds will exhibit an IC 50 with respect to K-RAS of not more than about 1 mM, as measured in the K-RAS assay described herein. In yet further embodiments, compounds will exhibit an IC 50 with respect to K-RAS of not more than about 200 nM.
• the K-RAS inhibitor is an irreversible inhibitor by way of covalent bond formation to the cysteine at the G12C mutation site.
• terapéuticaally effective is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder. This amount will achieve the goal of reducing or eliminating the the disease or disorder.
• subject means all mammals, including humans. Examples of subjects include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits. In some embodiments, the subject is a human.
• prodrug refers to a compound that is made active in vivo through chemical reaction in vivo thereby releasing an active compound.
• Compounds disclosed herein can be modified to exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003).
• Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the active compound. Additionally, prodrugs can be converted to the active compounds by chemical or biochemical methods in an ex vivo environment.
• prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
• Prodrugs are often useful because, in some situations, they may be easier to administer than the active compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not.
• the prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
• a wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
• prodrug is a compound which is administered as an ester (the “prodrug”), which is then metabolically hydrolyzed to the carboxylic acid, as the active entity. Additional examples include peptidyl derivatives of a compound.
• therapeutically acceptable prodrug refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of subjects without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• Z 1 and Z 2 are independently CR 6 or N, with the proviso that at least one of Z 1 or Z 2 is CR 6 with R 6 being a bond to L 1 ;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, alkoxy, aryl, heteroaryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, and arylthio with the proviso that:
• n is an integer from 1 to 3;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• R 6 is selected from the group consisting of hydrogen, alkyl, haloakyl, cyano, halo, alkoxy, aryl, heteroaryl, trifluoromethyl and bond to L 1 .
• j is 1.
• n is 0. In one or more of the preceding embodiments, m is 1.
• Z 1 is CR 6 with R 6 being a bond to L 1 .
• Z 2 is N.
• L 1 is
• k is an integer from 0 to 4; and each R 7 is independently selected from methyl, and cyanomethyl.
• E is an acrylyl group having optional substitution R:
• R is selected from the group consisting of fluorine, methyl, and —CH 2 NR a R b , wherein R a and R b are independently selected from hydrogen or alkyl; or R a and R b combine to form a C 2 -C 6 nitrogen containing heterocycle.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• j is 1.
• n is 0. In one or more of the preceding embodiments, m is 1.
• L 1 is
• k is an integer from 0 to 4; and each R 7 is independently selected from methyl, and cyanomethyl.
• E is an acrylyl group having optional substitution R:
• R is selected from the group consisting of fluorine, methyl, and —CH 2 NR a R b , wherein W and R b are independently selected from hydrogen or alkyl; or R a and R b combine to form a C 2 -C 6 nitrogen containing heterocycle.
• Ar creates axial asymmetry.
• the compound is a single rotamer.
• Ar is:
• R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, haloalkyl, trifluoromethyl, cycloalkyl and any two adjacent R 9 , R 10 , R 11 , R 12 , and R 13 together combine to form a further fused ring that is an aromatic ring optionally comprising 1 to 3 heteroatoms independently selected from N, O or S, the further fused ring being optionally substituted.
• X is O, S(O) p CR 3 R 4 , NR 5 , or C(O), wherein p is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of hydrogen, alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• X is O.
• L 1 is
• k is an integer from 0 to 4; and each R 7 is independently selected from methyl and cyanomethyl;
• E is an acrylyl group having optional substitution R:
• R is selected from the group consisting of fluorine, methyl, and —CH 2 NR a R b , wherein R a and R b are independently selected from hydrogen or alkyl; or R a and R b combine to form a C 2 -C 6 nitrogen containing heterocycle.
• optional substitution comprises monofluorination.
• Ar creates axial asymmetry.
• the compound is a single rotamer.
• Ar is:
• R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, haloalkyl, trifluoromethyl, cycloalkyl and any two adjacent R 9 , R 10 , R 11 , R 12 , and R 13 together combine to form a further fused ring that is an aromatic ring optionally comprising 1 to 3 heteroatoms independently selected from N, O or S, the further fused ring being optionally substituted.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• R 8 is selected from the group consisting of fluorine, methyl, and —CH 2 NR a R b , wherein R a and R b are independently selected from hydrogen or alkyl; or R a and R b combine to form a C 2 -C 6 nitrogen containing heterocycle; and
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• X is O, S(O) p CR 3 R 4 , NR 5 , or C(O), wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• G is selected from the group consisting of N, CH, and
• G 1 and G 2 are independently (CH 2 ) q , where q is 1 or 2;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• k is an integer from 0 to 4; and each R 7 is independently selected from methyl and cyanomethyl; and
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, and heteroaryl, any of which are optionally substituted;
• R 6 is is selected from the group consisting of hydrogen, alkyl, haloakyl, cyano, halo, alkoxy, aryl, heteroaryl, and trifluoromethyl;
• R 8 is selected from the group consisting of fluorine, methyl, and —CH 2 NR a R b , wherein R a and R b are independently selected from hydrogen or alkyl; or R a and R b combine to form a C 2 -C 6 nitrogen containing heterocycle; and
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• j is 1.
• n is 0. In one or more of the preceding embodiments, m is 1.
• L 1 is
• k is an integer from 0 to 4; and each R 7 is independently selected from methyl and cyanomethyl;
• Ar creates axial asymmetry.
• the compound is a single rotamer.
• Ar is:
• R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, haloalkyl, trifluoromethyl, cycloalkyl and any two adjacent R 9 , R 10 , R 11 , R 12 , and R 13 together combine to form a further fused ring that is an aromatic ring optionally comprising 1 to 3 heteroatoms independently selected from N, O or S, the further fused ring being optionally substituted.
• compounds of formulas I, II, III, VI, IX, and XX characterized as being CNS penetrant as measured by a quantity in a rat brain model (when tested at 2 mg/kg after IV dosing) having a concentration value in the rat brain expressed in ng/g (ng of compound per gram of tissue).
• the concentration value in the rat brain is at least 60 ng/g.
• the concentration is in a range from about 40 ng/g to about 300 ng/g.
• the concentration is in a range from about 40 n/g to about 60 ng/g.
• the concentration is in a range from 50 ng/g to about 300 ng/g.
• the concentration is in a range from about 60 ng/g to about 300 ng/g. In embodiments, the concentration is in a range from about 100 ng/g to about 300 ng/g. In embodiments, the concentration is in a range from about 150 ng/g to about 300 ng/g. In embodiments, the concentration is from about 150 ng/g to about 275 ng/g.
• compositions which comprise one or more of the compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers and optionally one or more other therapeutic ingredients.
• the carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen.
• compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
• the pharmaceutical compositions may include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
• the pharmaceutical composition may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound disclosed herein or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients.
• active ingredient a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof
• the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation
• compositions of the various embodiments disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
• the active ingredient may also be presented as a bolus, electuary or paste.
• compositions that can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
• compositions disclosed herein may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
• Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
• the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
• the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
• sterile liquid carrier for example, saline or sterile pyrogen-free water
• Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
• Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
• Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
• Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
• the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
• the compounds disclosed herein may be administered orally or via injection at a dose of from 0.1 to 500 mg/kg per day.
• a common dose range for adult humans is generally from 5 mg to 2 g/day.
• Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
• the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
• the compounds disclosed herein can be administered in various modes, e.g. orally, topically, or by injection.
• the precise amount of compound administered to a subject will be the responsibility of the attendant physician.
• the specific dose level for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated.
• the route of administration may vary depending on the condition and its severity.
• the compounds described herein may be administered in combination with another therapeutic agent.
• the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
• the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.
• Some embodiments relate to methods of using the compounds described herein to treat cell proliferative disorders, such as cancer.
• the cancer can be any cancer, including those described herein.
• the cancer can be, for example, a RAS associated cancer.
• the treatments can include the use of combination treatments as described herein.
• the cancer is a cancer of the central nervous system (CNS).
• CNS cancer can include any cancer of the CNS including cancer of the brain, spinal cord and nerves.
• Such CNS cancers can include, for example, primary cancers (e.g., those that start in the brain) and secondary or metastatic CNS cancers (those that do not start in the CNS but metastasize to the CNS).
• the CNS cancer can be a RAS associated cancer.
• Any CNS cancer is contemplated including without limitation, for example, gliomas (including astrocytomas and glioblastomas, oligodendrogliomas, ependymomas), meningiomas, medulloblastomas, ganbliogliomas, schwannomas, and craniopharyngiomas.
• Any metastatic CNS cancer is contemplated, including without limitation, a cancer metastasized to the CNS via metastases of melanoma, breast cancer, colon cancer, kidney cancer, nasopharyngeal cancer, lymphoma, myeloma, leukemia, and other cancers of unknown primary site.
• Some embodiments relate to treating, reducing or preventing metastesis of a CNS cancer, for example, to another region of the CNS and/or outside of the CNS.
• embodiments herein provide methods for treating a RAS associated cancer, for example, a K-RAS-mediated disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of the various embodiments disclosed herein effective to reduce or prevent said disorder in the subject in combination with at least one additional agent for the treatment of said disorder that is known in the art.
• the various embodiments disclosed herein provides therapeutic compositions comprising at least one compound of the various embodiments disclosed herein in combination with one or more additional agents for the treatment of K-RAS-mediated disorders.
• the K-RAS-mediated disease is cancer and the K-RAS presents in an oncogenic mutated form.
• Compounds disclosed herein may be useful in treating K-RAS-mediated disease, disorders and conditions.
• the compounds disclosed herein may be used in treating cancer, as disclosed hereinabove.
• the type of cancer may depend on presentation of a particular type of oncogenic mutation of K-RAS.
• oncogenic K-RAS mutations may be tied to human cancer of the pancreas, lung, and/or colon.
• Compounds disclosed herein may be used in combination therapies.
• the compounds disclosed herein may be used in combination with inhibitors of mammalian target of rapamycin (mTOR), insulin growth factor 1 receptor (IGF1R), and combinations thereof.
• mTOR mammalian target of rapamycin
• IGF1R insulin growth factor 1 receptor
• Such combination therapies may be particularly suited to certain cancer types such as lung cancer. See Molinas-Arcas et al. Sci. Trans. Med. 18 Sep. 2019 11:510 eaaw7999 at stm.sciencemag.org/content/11/510/eaaw7999.
• Compounds disclosed herein may be combined with modulators the ULK family of proteins, which regulate autophagy.
• Other compounds of interest in combination therapy include inhibitors of SHP2.
• SHP2 inhibitors include those disclosed in WO2016/203404, WO2018/136264, WO2018/057884, WO2019/067843, WO2019/183367, WO2016/203405, WO2019/051084, WO2018/081091, WO2019/165073, WO2017/216706, WO2018/218133, WO2019/183364, WO 2020061103, and WO2020061101. All references and patent applications, including compositions, methods of using, and methods of making compounds disclosed therein are incorporated herein by reference in their entirety.
• compounds disclosed herein may be combined with an EGFR inhibitor.
• the EGFR inhibitor is selective for a mutant EGFR, including, without limitation, C797X, L718Q, G724S, S768I, G719X, L792X, G796X, T263P, A289D/V, G598V, and EGFRvIII high expression.
• the combination therapy with EGFR agents tracked by mutation and indication are shown in Table 1 CT-1 below.
• EGFR inhibitors include those disclosed in U.S. Pat. Nos. 5,747,498, 8,946,235, and 9,732,058, WO2002030926, US 20040048880, US20050165035, and WO2019067543. All patents and applications, including compositions, methods of using, and methods of making compounds disclosed therein are incorporated herein by reference in their entirety.
• the second agent of the pharmaceutical combination formulation or dosing regimen may have complementary activities to the compounds disclosed herein such that they do not adversely affect each other.
• the compounds may be administered together in a unitary pharmaceutical composition or separately.
• a compound or a pharmaceutically acceptable salt can be co-administered with a cytotoxic agent to treat proliferative diseases and cancer.
• co-administering refers to either simultaneous administration, or any manner of separate sequential administration, of a compound disclosed herein or a salt thereof, and a further active pharmaceutical ingredient or ingredients, including cytotoxic agents and radiation treatment. If the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
• Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen.
• those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
• compositions of this invention are formulated such that a dosage of between 0.01-100 mg/kg body weight/day of an inventive can be administered.
• any agent that has activity against a disease or condition being treated may be co-administered.
• agents can be found in Cancer Principles and Practice of Oncology by V. T. Devita and S. Hellman (editors), 6 th edition (Feb. 15, 2001), Lippincott Williams & Wilkins Publishers.
• a person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the disease involved.
• the treatment method includes the co-administration of a compound disclosed herein or a pharmaceutically acceptable salt thereof and at least one cytotoxic agent.
• cytotoxic agent refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
• Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu); chemotherapeutic agents; growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.
• radioactive isotopes e.g., At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu
• chemotherapeutic agents e.g., At 211 , I 131 , I 125
• Exemplary cytotoxic agents can be selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A; inhibitors of fatty acid biosynthesis; cell cycle signalling inhibitors; HDAC inhibitors, proteasome inhibitors; and inhibitors of cancer metabolism.
• “Chemotherapeutic agent” includes chemical compounds useful in the treatment of cancer.
• chemotherapeutic agents include erlotinib (TARCEVA®, Genentech/OSI Pharm.), bortezomib (VELCADE®, Millennium Pharm.), disulfiram, epigallocatechin gallate, salinosporamide A, carfilzomib, 17-AAG(geldanamycin), radicicol, lactate dehydrogenase A (LDH-A), fulvestrant (FASLODEX®, AstraZeneca), sunitib (SUTENT®, Pfizer/Sugen), letrozole (FEMARA®, Novartis), imatinib mesylate (GLEEVEC®, Novartis), finasunate (VATALANIB®, Novartis), oxaliplatin (ELOXATIN®, Sanofi), 5-FU (5-fluorouracil), leucovorin, Rapamycin (Sirol
• dynemicin including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® (doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, es
• Chemotherapeutic agent also includes (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX®; tamoxifen citrate), raloxifene, droloxifene, iodoxyfene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON® (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozole, RIVISOR® (vorozole), FEMARA® (let
• Chemotherapeutic agent also includes antibodies such as alemtuzumab (Campath), bevacizumab (AVASTINO, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech/Biogen Idec), pertuzumab (OMNITARG®, 2C4, Genentech), trastuzumab (HERCEPTINO, Genentech), tositumomab (Bexxar, Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth).
• antibodies such as alemtuzumab (Campath), bevacizumab (AVASTINO, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab (VECTIBIX®, Amgen), rituximab
• Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizum
• Chemotherapeutic agent also includes “EGFR inhibitors,” which refers to compounds that bind to or otherwise interact directly with EGFR and prevent or reduce its signaling activity, and is alternatively referred to as an “EGFR antagonist.”
• EGFR inhibitors refers to compounds that bind to or otherwise interact directly with EGFR and prevent or reduce its signaling activity
• Examples of such agents include antibodies and small molecules that bind to EGFR.
• antibodies which bind to EGFR include MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509) (see, U.S. Pat. No.
• the anti-EGFR antibody may be conjugated with a cytotoxic agent, thus generating an immunoconjugate (see, e.g., EP659,439A2, Merck Patent GmbH).
• EGFR antagonists include small molecules such as compounds described in U.S. Pat. Nos.
• EGFR antagonists include OSI-774 (CP-358774, erlotinib, TARCEVA® Genentech/OSI Pharmaceuticals); PD 183805 (CI 1033, 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA®) 4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperid
• Chemotherapeutic agents also include “tyrosine kinase inhibitors” including the EGFR-targeted drugs noted in the preceding paragraph; small molecule HER2 tyrosine kinase inhibitor such as TAK165 available from Takeda; CP-724,714, an oral selective inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI); dual-HER inhibitors such as EKB-569 (available from Wyeth) which preferentially binds EGFR but inhibits both HER2 and EGFR-overexpressing cells; lapatinib (GSK572016; available from Glaxo-SmithKline), an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166 (available from Novartis); pan-HER inhibitors such as canertinib (CI-1033; Pharmacia); Raf-1 inhibitors such as antisense agent ISIS-5132 available from ISIS Pharmaceuticals which inhibit Raf-t signaling; non-HER targeted
• Chemotherapeutic agents also include dexamethasone, interferons, colchicine, metoprine, cyclosporine, amphotericin, metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide, asparaginase, BCG live, bevacuzimab, bexarotene, cladribine, clofarabine, darbepoetin alfa, denileukin, dexrazoxane, epoetin alfa, elotinib, filgrastim, histrelin acetate, ibritumomab, interferon alfa-2a, interferon alfa-2b, lenalidomide, levamisole, mesna, methoxsalen, nandrolone, nelarabine, nofetumomab, oprelvekin,
• Chemotherapeutic agents also include hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-butyrate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate and fluprednidene acetate; immune selective
• celecoxib or etoricoxib proteosome inhibitor
• CCI-779 tipifarnib (R11577); orafenib, ABT510
• Bcl-2 inhibitor such as oblimersen sodium (GENASENSE®)
• pixantrone farnesyltransferase inhibitors
• SCH 6636 farnesyltransferase inhibitors
• pharmaceutically acceptable salts, acids or derivatives of any of the above as well as combinations of two or more of the above such as CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone
• FOLFOX an abbreviation for a treatment regimen with oxaliplatin (ELOXATINTM) combined with 5-FU and leucovorin.
• Chemotherapeutic agents also include non-steroidal anti-inflammatory drugs with analgesic, antipyretic and anti-inflammatory effects.
• NSAIDs include non-selective inhibitors of the enzyme cyclooxygenase.
• Specific examples of NSAIDs include aspirin, propionic acid derivatives such as ibuprofen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and naproxen, acetic acid derivatives such as indomethacin, sulindac, etodolac, diclofenac, enolic acid derivatives such as piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam and isoxicam, fenamic acid derivatives such as mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, and COX-2 inhibitors such as celecoxib, etoricoxib, lumirac
• NSAIDs can be indicated for the symptomatic relief of conditions such as rheumatoid arthritis, osteoarthritis, inflammatory arthropathies, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, acute gout, dysmenorrhoea, metastatic bone pain, headache and migraine, postoperative pain, mild-to-moderate pain due to inflammation and tissue injury, pyrexia, ileus, and renal colic.
• conditions such as rheumatoid arthritis, osteoarthritis, inflammatory arthropathies, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, acute gout, dysmenorrhoea, metastatic bone pain, headache and migraine, postoperative pain, mild-to-moderate pain due to inflammation and tissue injury, pyrexia, ileus, and renal colic.
• chemotherapeutic agents include, but are not limited to, doxorubicin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, interferons, platinum derivatives, taxanes (e.g., paclitaxel, docetaxel), vinca alkaloids (e.g., vinblastine), anthracyclines (e.g., doxorubicin), epipodophyllotoxins (e.g., etoposide), cisplatin, an mTOR inhibitor (e.g., a rapamycin), methotrexate, actinomycin D, dolastatin 10, colchicine, trimetrexate, metoprine, cyclosporine, daunorubicin, teniposide, amphotericin, alkylating agents (e.g., chlorambucil), 5-fluorouracil, campthothecin, cisplatin
• compounds disclosed herein, or a pharmaceutically acceptable composition thereof are administered in combination with an antiproliferative or chemotherapeutic agent selected from any one or more of abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG live, bevacuzimab, fluorouracil, bexarotene, bleomycin, bortezomib, busulfan, calusterone, capecitabine, camptothecin, carboplatin, carmustine, cetuximab, chlorambucil, cladribine, clofarabine, cyclophosphamide, cytarabine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin, dexrazoxan
• Chemotherapeutic agents also include treatments for Alzheimer's Disease such as donepezil hydrochloride and rivastigmine; treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating multiple sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), glatiramer acetate, and mitoxantrone; treatments for asthma such as albuterol and montelukast sodium; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cycl
• chemotherapeutic agents include pharmaceutically acceptable salts, acids or derivatives of any of chemotherapeutic agents, described herein, as well as combinations of two or more of them.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• Z 1 and Z 2 are independently CR 6 or N, with the proviso that at least one of Z 1 or Z 2 is CR 6 with R 6 being a bond to L 1 ;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, alkoxy, aryl, heteroaryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, and arylthio with the proviso that:
• n is an integer from 1 to 3;
• R 2 is selected from the group consisting of alkyl, amino, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, hydroxy, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, and oxo any of which are optionally substituted; or two R 2 together with the carbon atom to which they are attached form a spirocycle or heterocycle.
• n is an integer from 0 to 6;
• R 6 is selected from the group consisting of hydrogen, alkyl, haloakyl, cyano, halo, alkoxy, aryl, heteroaryl, trifluoromethyl and bond to L 1 .
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• X is S(O) p , wherein p is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy; n is an integer from 0 to 2; and
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• c is an integer from 0 to 4.
• A is selected from the group consisting of hydroxyl, amino, N-alkylamino, N,N-dialkylamino, cycloalkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, cycloalkylaminoalkyl, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted; and
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 8 is selected from the group consisting of fluorine, methyl, and —CH 2 NR a R b , wherein R a and R b are independently selected from hydrogen or alkyl; or R a and R b combine to form a C 2 -C 6 nitrogen containing heterocycle; and
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• L 1 is linking group comprising at least one nitrogen atom
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• L 1 is linking group comprising at least one nitrogen atom
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• c is an integer from 0 to 4.
• A is selected from the group consisting of hydroxyl, amino, N-alkylamino, N,N-dialkylamino, cycloalkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, cycloalkylaminoalkyl, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted; and
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• G is selected from the group consisting of N, CH, and
• G 1 and G 2 are independently (CH 2 ) q , where q is 1 or 2;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• each R 7 is independently selected from an alkyl group selected from methyl, ethyl, and propyl, any of which are optionally substituted with one or more fluorine atoms, —CH 2 (CH 3 )C ⁇ CF 2 , cyano, propargyl, —CH 2 C(O)V, wherein V is selected from methyl, OH, NHR i wherein R i is hydrogen or alkyl, and cyanomethyl; or any two R 7 may combine to form a fused-ring, spiro or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, SO 2 , or NR j , wherein R j is H, methyl or trifluoromethyl; and
• G is selected from the group consisting of N, CH, and
• G 1 and G 2 are independently (CH 2 ) q , where q is 1 or 2;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 4.
• each R 7 is independently selected from an alkyl group selected from methyl, ethyl, and propyl, any of which are optionally substituted with one or more fluorine atoms, —CH 2 (CH 3 )C ⁇ CF 2 , cyano, propargyl, —CH 2 C(O)V, wherein V is selected from methyl, OH, NHR i wherein R i is hydrogen or alkyl, and cyanomethyl; or any two R 7 may combine to form a fused-ring, spiro or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, SO 2 , or NR j , wherein R j is H, methyl or trifluoromethyl; and
• G is selected from the group consisting of N, CH, and
• G 1 and G 2 are independently (CH 2 ) q , where q is 1 or 2;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted;
• c is an integer from 0 to 4.
• A is selected from the group consisting of hydroxyl, amino, N-alkylamino, N,N-dialkylamino, cycloalkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, cycloalkylaminoalkyl, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• each R 7 is independently selected from an alkyl group selected from methyl, ethyl, and propyl, any of which are optionally substituted with one or more fluorine atoms, —CH 2 (CH 3 )C ⁇ CF 2 , cyano, propargyl, —CH 2 C(O)V, wherein V is selected from methyl, OH, NHR i wherein R i is hydrogen or alkyl, and cyanomethyl; or any two R 7 may combine to form a fused-ring, spiro or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, SO 2 , or NR j , wherein R j is H, methyl or trifluoromethyl; and wherein the acrylyl moiety linked to G is optionally substituted.
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted;
• c is an integer from 0 to 4.
• A is selected from the group consisting of hydroxyl, amino, N-alkylamino, N,N-dialkylamino, cycloalkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, cycloalkylaminoalkyl, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• each R 7 is independently selected from an alkyl group selected from methyl, ethyl, and propyl, any of which are optionally substituted with one or more fluorine atoms, —CH 2 (CH 3 )C ⁇ CF 2 , cyano, propargyl, —CH 2 C(O)V, wherein V is selected from methyl, OH, NHR i wherein R i is hydrogen or alkyl, and cyanomethyl; or any two R 7 may combine to form a fused-ring, spiro or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, SO 2 , or NR j , wherein R j is H, methyl or trifluoromethyl; and
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted;
• c is an integer from 0 to 4.
• A is selected from the group consisting of hydroxyl, amino, N-alkylamino, N,N-dialkylamino, cycloalkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, cycloalkylaminoalkyl, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• R 7A , R 7B , R 7C , and R 7D are independently selected from hydrogen, alkyl, and cyanoalkyl; or any two R 7A-D may combine to form a fused-ring or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, or SO 2 . and
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted;
• R 7A , R 7B , R 7C , and R 7D are independently selected from hydrogen, alkyl, and cyanoalkyl; or any two R 7A-D may combine to form a fused-ring or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, or SO 2 ; and
• R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, haloalkyl, trifluoromethyl, cycloalkyl and any two adjacent R 9 , R 10 , R 11 , R 12 , and R 13 together combine to form a further fused ring that is an aromatic ring optionally comprising 1 to 3 heteroatoms independently selected from N, O or S, the further fused ring being optionally substituted.
• E is an electrophilic moiety
• G is selected from the group consisting of N, CH, and
• G 1 and G 2 are independently (CH 2 ) q , where q is 1 or 2;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 7A , R 7B , R 7C , and R 7D are independently selected from hydrogen, alkyl, and cyanoalkyl; or any two R 7A-D may combine to form a fused-ring or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, or SO 2 .
• R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, haloalkyl, trifluoromethyl, cycloalkyl and any two adjacent R 9 , R 10 , R 11 , R 12 , and R 13 together combine to form a further fused ring that is an aromatic ring optionally comprising 1 to 3 heteroatoms independently selected from N, O or S, the further fused ring being optionally substituted;
• R 14 and R 15 are selected from the group consisting of hydrogen, hydroxyl, amino, N-alkylamino, dialkylamino, N-alkylamino alkyl, N,N-dialkylamino, N,N-dialkylamino alkyl, cycloalkylamino, cycloalkylaminoalkyl, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted, with the proviso that one of R 14 or R 15 is hydrogen; and
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 7A , R 7B , R 7C , and R 7D are independently selected from hydrogen, alkyl, and cyanoalkyl; or any two R 7A-D may combine to form a fused-ring or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, or SO 2 .
• R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, haloalkyl, trifluoromethyl, cycloalkyl and any two adjacent R 9 , R 10 , R 11 , R 12 , and R 13 together combine to form a further fused ring that is an aromatic ring optionally comprising 1 to 3 heteroatoms independently selected from N, O or S, the further fused ring being optionally substituted.
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 7A , R 7B , R 7C , and R 7D are independently selected from hydrogen, alkyl, and cyanoalkyl; or any two R 7A-D may combine to form a fused-ring or bridging bicycle, wherein any one fused-ring or bridging atom is O, S, S ⁇ O, or SO 2 .
• R 9 , R 10 , R 11 , R 12 , and R 13 are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, haloalkyl, trifluoromethyl, cycloalkyl and any two adjacent R 9 , R 10 , R 11 , R 12 , and R 13 together combine to form a further fused ring that is an aromatic ring optionally comprising 1 to 3 heteroatoms independently selected from N, O or S, the further fused ring being optionally substituted.
• c is an integer from 0 to 4.
• A is selected from the group consisting of hydroxyl, amino, N-alkylamino, N,N-dialkylamino, cycloalkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, cycloalkylaminoalkyl, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted; and
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• L 1 is linking group comprising at least one nitrogen atom
• each R 1 is is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 0 to 2;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 6 is is selected from the group consisting of hydrogen, alkyl, haloakyl, cyano, halo, alkoxy, aryl, heteroaryl, and trifluoromethyl;
• R 8 is selected from the group consisting of fluorine, methyl, and —CH 2 NR a R b , wherein R a and R b are independently selected from hydrogen or alkyl; or R a and R b combine to form a C 2 -C 6 nitrogen containing heterocycle; and
• Ar is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, heteroaryl, N-heteroarylamino, N-heteroaryl-N-alkylamino, heteroaryloxy, or heteroarylthio, any of which is optionally substituted.
• Y is selected from the group consisting of hydrogen; N-linked heteroaromatic ring; N-linked azetidinyl optionally substituted with fluorine, CO—NR′R′′, or spiro-linked oxetane; OR a ; and Z 3 R b R c ;
• R′ and R′′ are independently hydrogen, alkyl or cycloalkyl
• Z 3 is CH, COH, or N;
• n is an integer from 1 to 5;
• R a is hydrogen, methyl, ethyl trifluoromethyl, heterocyclyl, or heterocyclylalkyl
• R b and R c are independently selected from alkyl, alkyl having one or more fluorine substitutions, cycloalkyl, oxetanyl, and N-methyl prolinyl; or R b and R c combine to form a cyclic structure A1:
• M is selected from a bond, O, S, SO, SO 2 , CH 2 , NH, NMe, N-ethyl, N-oxetanyl, and N-cyclopropyl, wherein each C—H of each alkylene, alkyl or cycloalkyl group is independently optionally substituted with a fluorine atom;
• each R s is independently fluorine, oxo, alkoxy, or CO—NR′R′′, or any two R s combine to form a 1 to 3 carbon atom bridge, wherein the 1 to 3 carbon atom bridge is optionally substituted with one or more fluorine atoms;
• each R′ and R′′ is independently hydrogen, alkyl or cycloalkyl
• j is an integer from 0 to 2;
• Z 1 and Z 2 are independently CR 6 or N, with the proviso that at least one of Z 1 or Z 2 is CR 6 with R 6 being a bond to L 1 ;
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is independently selected from the group consisting of acyl, alkyl, carboxamide, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, alkoxy, aryl, heteroaryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, cycloalkyl, heterocyclyl, and arylthio with the proviso that at least one R 1 is aryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, arylthio, or heteroaryl, any of which is optionally substituted;
• n is an integer from 1 to 3;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, heteroaryl, and cycloalkyl, any of which are optionally substituted; and
• R 6 is selected from the group consisting of hydrogen, alkyl, haloakyl, cyano, halo, alkoxy, aryl, heteroaryl, trifluoromethyl and bond to L 1 , and pharmaceutically acceptable salts thereof.
• X is S(O) p , wherein p is an integer from 0 to 2;
• j is an integer from 0 to 2;
• B is bridging group comprising 1 to 3 carbon atoms, wherein any one carbon atom is optionally replaced by O, S, SO 2 , or N-alkyl;
• E is an electrophilic moiety
• each R 1 is independently selected from the group consisting of acyl, alkyl, carboxamide, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, alkoxy, aryl, heteroaryl, N-arylamino, N-aryl-N-alkylamino, aryloxy, cycloalkyl, heterocyclyl, and arylthio with the proviso that:
• n is an integer from 1 to 3;
• R 2 is selected from the group consisting of alkyl, alkylamino, dialkylamino, alkylamidoalkyl, arylamidoalkyl, alkylsulfonamidoalkyl, arylsulfonamidoalkyl, N-alkyl aminoalkyl, N,N-dialkyl aminoalkyl, amido, amido alkyl, alkoxy, alkoxyalkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, halo, haloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, any of which are optionally substituted;
• n is an integer from 0 to 6;
• R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen alkyl, halo, alkoxy, aryl, heteroaryl, and cycloalkyl, any of which are optionally substituted, and pharmaceutically acceptable salts thereof.
• X is O or S
• L 1 is linking group comprising at least one nitrogen atom
• E is an electrophilic moiety, wherein E is bound to L 1 via the at least one nitrogen atom;
• each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cycloalkyl, halo, haloalkyl, trifluoromethyl, and alkoxy;
• n is an integer from 1 to 2;
• each R 2 is independently selected from the group consisting optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —CHR′R′′, —OR′, —SR′, and —NR′,R′′; wherein each R′ or R′′ is selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, hydroxy, cycloalkoxy, cyano , cyanoalkyl, amido, amidoalkyl, N-alkylamido, N-alkylamidoalkyl, N,N-dialkylamido, N,N-dialkylamidoalkyl, amino, aminoalkyl, N-alkyl amino, N-alkyl aminoalkyl, N,N-dialkylamino, and N,N-dialkylaminoalkyl, any of which are optionally substituted; or any two R′ and R′′ combine to form 3-7-membered ring, optionally comprising 1 or 2 hetero
• n is an integer from 0 to 6.
• L 1 is linking group comprising at least one nitrogen atom; each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cyclopropyl, halo, haloalkyl, trifluoromethyl, alkoxy, n is 1 or 2; each R 2 is independently selected from the group consisting optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —CHR′R′′, —OR′, —SR′, and —NR′,R′′; wherein each R′ or R′′ is selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, hydroxy, cycloalkoxy, cyano, cyanoalkyl, amido, amidoalkyl, N-alkylamido, N-alkylamidoalkyl, N,N-dialkylamido, N,N-dialkylamidoalkyl, amino, aminoalkyl, N-alkyl
• L 1 is linking group comprising at least one nitrogen atom; each R 1 is an optional substitution independently selected from the group consisting of alkyl, cyano, cyclopropyl, halo, haloalkyl, trifluoromethyl, alkoxy, n is 1 or 2; R 2a and R 2b are independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —CHR′R′′, —OR′, —SR′, and —NR′,R′′; wherein each R′ or R′′ is selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, hydroxy, cycloalkoxy, cyano , cyanoalkyl, amido, amidoalkyl, N-alkylamido, N-alkylamidoalkyl, N,N-dialkylamido, N,N-dialkylamidoalkyl, amino, aminoalkyl
• Ar is a phenyl optionally substituted with one or more alkyl, cycloalkyl, fluoro, chloro, bromo, iodo, trifluoromethyl or cyano.
• k is an integer from 0 to 4; and each R 7 is independently selected from methyl, and cyanomethyl, or any two R 7 combine to form a bridge or spirocycle structure optionally comprising a heteroatom in the bridge or spirocycle selected from S, SO 2 , O or N, and wherein the bridge or spirocycle structure is optionally substituted with oxo.
• a pharmaceutical composition comprising a compound of embodiments 353 to 377.
• a method of treating a subject with a cancer comprising a K-Ras G12C mutation comprising administering to the subject a compound of any one of embodiments 353 to 377 or pharmaceutical composition thereof.
• Example 84 7-(9-acryloyl-3,3-dioxido-3-thia-7,9-diazabicyclo[3.3.1]nonan-7-yl)-9-chloro-10-(2,4-difluorophenyl)-2,3-dihydro-5H-[1,4]thiazino[2,3,4-ij]quinazolin-5-one
• Step 2 diethyl 3,3′-((phenylsulfonyl)azanediyl)bis(2-bromopropanoate)
• Step 3 d ethyl-1-benzyl-4-(phenylsulfonyl)piperazine-cis-2,6-dicarboxylate
• Step 5 1-benzyl-cis-(2,6-bis(chloromethyl))-4-(phenylsulfonyl)piperazine
• Step 7 tert-butyl-9-benzyl-3-thia-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate
• Step 8 tert-butyl-9-benzyl-3-thia-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate 3,3-dioxide
• Step 9 tert-butyl-3-thia-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate 3,3-dioxide
• Methyl 4-bromo-5-chloro-2-acetamidobenzoate (47 g, 0.15 mol) was dissolved in a methanolic solution of HCl (5M, 500 mL) and the mixture stirred at 80° C. for 2 hours. The reaction was diluted with water (500 mL) and filtered to afford methyl 2-amino-4-bromo-5-chlorobenzoate (crude, 39 g, 90%) as a white solid.
• Step 15 methyl 5-amino-2-chloro-2′,4′-difluoro-[1,1′-biphenyl]-4-carboxylate
• Step 16 methyl 3-amino-6-chloro-2′,4′-difluoro-2-iodo-[1,1′-biphenyl]-4-carboxylate
• Step 17 3-amino-6-chloro-2′,4′-difluoro-2-iodo-[1,1′-biphenyl]-4-carboxylic acid
• Step 18 6-chloro-7-(2,4-difluorophenyl)-8-iodoquinazoline-2,4(1H,3H)-dione
• Step 19 6-chloro-7-(2,4-difluorophenyl)-8-((2-hydroxyethyl)thio)quinazoline-2,4(1H,3H)-dione
• Step 20 9-chloro-10-(2,4-difluorophenyl)-2,3-dihydro-5H-[1,4]thiazino[2,3,4-ij]quinazoline-5,7(6H)-dione
• Step 21 9-chloro-10-(2,4-difluorophenyl)-7-(3,3-dioxido-3-thia-7,9-diazabicyclo[3.3.1]nonan-7-yl)-2,3-dihydro-5H-[1,4]thiazino[2,3,4-ij]quinazolin-5-one
• Example 100 7-(4-acryloyl-6,6-dioxidohexahydrothieno[3,4-b]pyrazin-1(2H)-yl)-10-(2,4-difluorophenyl)-9-(trifluoromethyl)-2,3-dihydro-5H-[1,4]thiazino[2,3,4-ij]quinazolin-5-one
• Example 84 The title compound was prepared analogously to Example 84 where 10-(2,4-difluorophenyl)-7-(6,6-dioxidohexahydrothieno[3,4-b]pyrazin-1(2H)-yl)-9-(trifluoromethyl)-2,3-dihydro-5H-[1,4]thiazino[2,3,4-ij]quinazolin-5-one was substituted in place of 9-chloro-10-(2,4-difluorophenyl)-7-(3,3-dioxido-3-thia-7,9-diazabicyclo[3.3.1]nonan-7-yl)-2,3-dihydro-5H-[1,4]thiazino[2,3,4-ij]quinazolin-5-one.
• Step 1 methyl 3-amino-2′,4′-difluoro-[1,1′-biphenyl]-4-carboxylate
• Step 2 methyl 5-amino-2′,4′-difluoro-2-iodo-[1,1′-biphenyl]-4-carboxylate
• Step 3 methyl 5-acetamido-2′,4′-difluoro-2-iodo-[1,1′-biphenyl]-4-carboxylate
• Step 4 methyl 5-acetamido-2′,4′-difluoro-2-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylate
• Step 5 methyl 5-amino-2′,4′-difluoro-2-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylate
• Step 6 methyl 3-amino-2′,4′-difluoro-2-iodo-6-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylate
• Step 7 3-amino-2′,4′-difluoro-2-iodo-6-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylic acid
• Step 8 7-(2,4-difluorophenyl)-8-iodo-6-(trifluoromethyl)quinazoline-2,4(1H3H)-dione
• Step 9 7-(2,4-difluorophenyl)-8-((2-hydroxyethyl)thio)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione
• Step 10 10-(2,4-difluorophenyl)-9-(trifluoromethyl)-2,3-dihydro-5H-[1,4]thiazino[2,3,4-ij]quinazoline-5,7(6H)-dione
• Triphenylphosphine (1.69 g, 6.4 mmol) in THF (10 ml) cooled to 0° C. was added N,N-Diisopropylethylamine (1.30 g, 6.4 mmol) and stirred for 30 minutes.
• 7-(2,4-difluorophenyl)-8-((2-hydroxyethyl)thio)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (1.8 g, 6.4 mmol) was added and stirred at 0° C. for 1 hour.
• Step 11 diethyl pyrazine-2,3-dicarboxylate
• Step 12 syn-(diethyl-piperazine-2,3-dicarboxylate)
• Step 13 diethyl-1,4-dibenzylpiperazine-cis-2,3-dicarboxylate
• Step 15 1,4-dibenzylpiperazine-cis-2,3-diyl-bis(methylene) dimethanesulfonate
• Step 17 cis-octahydrothieno[3,4-b]pyrazine
• Step 18 dibenzyl-cis-hexahydrothieno[3,4-b]pyrazine-1,4-dicarboxylate
• Step 20 cis-octahydrothieno[3,4-b]pyrazine 6,6-dioxide

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (5)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=79687016

Family Applications (2)

Family Applications After (1)

Country Status (2)

Families Citing this family (6)

Family Cites Families (198)

• 2021
  • 2021-12-20 US US17/556,498 patent/US20230107642A1/en active Pending
  • 2021-12-20 WO PCT/US2021/064356 patent/WO2022133345A1/fr active Application Filing
• 2022
  • 2022-12-08 US US18/063,626 patent/US11845761B2/en active Active

Also Published As

Similar Documents

Legal Events